The American Society of Clinical Oncology’s (ASCO) annual meeting was held online from June 4 through June 8, 2021. During the conference, researchers presented new data on all subtypes of metastatic breast cancer.
Follow the links below to learn about health disparities in MBC treatment, treatment dosing options, new therapies for HER2-positive MBC, long-term survival data on CDK 4/6 inhibitors for hormone-positive MBC, triple-negative MBC subtypes, and several videos on treating brain mets.
All Metastatic Breast Cancer
- Breast Cancer Research Foundation: BCRF Investigators Highlight Work on Racial Disparities in Breast Cancer
- OncLive: ASCO 2021 Brings Increasing Recognition of Health Disparities in Cancer Care
- Breastcancer.org: Most Women With Metastatic Breast Cancer Have Troubling Treatment Side Effects, Willing To Discuss Dosing Options With Doctor
- The Video Journal of Oncology: PARPi for Somatic BRCA1/2 and other DNA Repair Gene Mutations in Women with Metastatic Breast Cancer
HER2-Positive Metastatic Breast Cancer
- Breastcancer.org: Adding Tukysa to Standard of Care Continues To Improve Survival in Advanced-Stage HER2-Positive Breast Cancer
- Practice Update: HER2CLIMB Update Shows Benefits of Adding Tucatinib to Trastuzumab and Capecitabine Are Maintained in Metastatic Breast Cancer
- The Video Journal of Oncology: Trastuzumab Deruxtecan in Patients with Breast Cancer and Brain Metastases in DESTINY-Breast01
- The Video Journal of Oncology: HER2CLIMB-04: Tucatinib plus T-DXd for HER2+ Breast Cancer
- The Video Journal of Oncology: Drug Repurposing in HER2+ Breast Cancer
- OncLive: Tucatinib Plus Trastuzumab/Capecitabine Maintain Survival Benefit in HER2-Positive Breast Cancer
Hormone-Positive Metastatic Breast Cancer
- Breastcancer.org: Kisqali-Faslodex Combo Continues To Improve Overall Survival in Advanced-Stage, Hormone-Receptor-Positive Breast Cancer in Postmenopausal Women
- Breastcancer.org: Ibrance-Faslodex Combo Continues To Improve Overall Survival in Advanced-Stage, Hormone-Receptor-Positive Breast Cancer
- Practice Update: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3
- Practice Update: Updated Results of MONALEESA-3 Show Sustained Overall Survival Benefits With Ribociclib in Advanced Breast Cancer
- Practice Update: Bone-Protective Effects of Everolimus for Premenopausal HR+/HER2- Metastatic Breast Cancer
- The Video Journal of Oncology: Phase I/II study of a novel SERCA in ER+ HER2- BC
- OncLive: Dr. Bardia on Ongoing Research With Amcenestrant and Palbociclib in ER+/HER2- Advanced Breast Cancer
- OncLive: Ribociclib/Fulvestrant Maintains Survival Benefit in Postmenopausal HR+ Advanced Breast Cancer, Irrespective of Setting
Triple-Negative Metastatic Breast Cancer
- Practice Update: IMpassion130 Analysis Identifies Tumor Immune Phenotypes and Molecular Subtypes Most Likely to Respond to Atezolizumab
Breast Cancer Brain/Leptomeningeal Metastases
- The Video Journal of Oncology: Immune Markers Predict Overall Survival in BC Patients with Brain Metastases
- The Video Journal of Oncology: PI3K Inhibitors for the Treatment of Brain Metastases in HER2-negative Breast Cancer
- The Video Journal of Oncology: Tucatinib in HER2+ Breast Cancer with Leptomeningeal Metastases
- The Video Journal of Oncology: Potential Treatment Approaches for Breast Cancer with Brain Metastases